Takeda Pharmaceutical Co. Ltd. and Eli Lilly and Co. have been ordered to pay a total of $9 billion in damages to users of the drug Actos after evidence linking its use to an increased risk of bladder cancer emerged. A Lafayette, Louisiana jury ordered Takeda to pay $6 billion in punitive damages and Eli Lilly to pay an additional $3 billion for the effects that the drug may have had on patients.

Actos is a medication used to treat Type 2 diabetes and was originally developed and distributed as a safer alternative to another medication used in the treatment of Type 2 diabetes, Avandia. However, more recent studies have found that the serious risks associated with Actos may make it more harmful than beneficial for patients.